Filing Details

Accession Number:
0001209191-13-030969
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-06-06 15:25:51
Reporting Period:
2013-06-05
Filing Date:
2013-06-06
Accepted Time:
2013-06-06 15:25:51
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1571498 Epizyme Inc. EPZM Pharmaceutical Preparations (2834) 261349956
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
816284 Celgene Corp /De/ 86 Morris Avenue
Summit NJ 07901
No No Yes No
1577650 Celgene European Investment Co Llc 86 Morris Avenue
Summit NJ 07901
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-06-05 3,267,974 $0.00 3,267,974 No 4 C Direct
Common Stock Acquisiton 2013-06-05 66,666 $15.00 3,334,640 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series C Preferred Stock Disposition 2013-06-05 9,803,922 $0.00 3,267,974 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
Footnotes
  1. Upon closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into 1/3rd of a share of Common Stock without payment of further consideration. The shares had no expiration date.
  2. These shares are owned directly by Celgene European Investment Company LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pencuniary interest therein.